CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema...
Phase 2
Detroit, Michigan, United States and 35 other locations
The purpose of this study is to test if treatment with tralokinumab is safe and effectful to treat moderate-to-severe atopic hand eczema. Th...
Phase 3
Detroit, Michigan, United States and 76 other locations
The study is focused on skin of color participants who have moderate-to-severe atopic dermatitis. Atopic dermatitis, also referred to as eczema...
Phase 4
Dearborn, Michigan, United States and 29 other locations
This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety...
Phase 2
Troy, Michigan, United States of America and 35 other locations
the treatment of adults with moderate to severe Atopic Dermatitis (Eczema). OpSCF will be compared to a placebo.OpSCF or placebo will be adm...
Phase 2
Auburn Hills, Michigan, United States and 21 other locations
The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atop...
Phase 3
Troy, Michigan, United States and 36 other locations
The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) pre...
Phase 3
Troy, Michigan, United States and 41 other locations
This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center proof-of-concept (POC) study in subjects with moderate to severe Atop...
Phase 2
Troy, Michigan, United States and 26 other locations
The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...
Phase 3
Detroit, Michigan, United States and 179 other locations
This study will evaluate the safety, tolerability, and efficacy of ANB032 in subjects with moderate to severe atopic dermatitis (AD).
Phase 2
Detroit, Michigan, United States and 79 other locations
Clinical trials
Research sites
Resources
Legal